Get our Drug Patent Expiration Bulletin:
Serving hundreds of leading biopharmaceutical companies globally:
Generated: November 15, 2018
DrugPatentWatch Database Preview
| Applicant | Generic Name | NDA | Strength | Dosage Form |
|---|---|---|---|---|
| Cipla Limited | lamivudine; zidovudine | 202814 | 30MG; 60MG | TABLET, FOR SUSPENSION; ORAL |
| Cipla Limited | efavirenz; emtricitabine; tenofovir disoproxil fumarate | 091593 | 300MG | TABLET; ORAL |
| Cipla Limited | lamivudine; zidovudine; nevirapine | 021971 | 150MG; 300MG; 200MG | TABLET; ORAL |
| Applicant | Generic Name | NDA | Strength | Dosage Form |
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch: